A prospective, multicentre, open-label single-arm exploratory study to evaluate efficacy and safety of saroglitazar on hypertriglyceridemia in HIV associated lipodystrophy

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Deshpande, Alka ^a   Toshniwal, Harsh ^b   Joshi, Shashank ^c   Jani, Rajendrakumar H ^d  

^a SIR J J GROUP OF HOSPITALS   (India)

^b IDTM Clinic   (India)

^c RESERVE BANK OF INDIA   (India)

^d ZYDUS RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SAROGLITAZAR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ALPHA-ETHOXY-4-(2-(2-METHYL-5-(4-METHYLTHIO)PHENYL))-1H-PYRROL-1-YL)ETHOXY))BENZENEPROPANOIC ACID; CHOLESTEROL; LIPOPROTEIN; PHENYLPROPIONIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MALE; MULTICENTER STUDY; OPEN STUDY; PANCREAS ISLET BETA CELL; STOMACH PAIN; ADOLESCENT; AGED; BLOOD; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; MIDDLE AGED; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CHOLESTEROL; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN; LIPOPROTEINS; MALE; MIDDLE AGED; PHENYLPROPIONATES; PROSPECTIVE STUDIES; PYRROLES;

EID: 84958559423     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146222     Document Type: Article

References (35)

1. Sutinen Jussi. The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Research, Volume 2009, Article ID 373524.
2. Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. CurrAtheroscler Rep. 2011; 13:51-6. doi: 10.1007/s11883-010-0152-1 PMID: 21181310
3. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, Capeau J, Cohen A. HIV and coronary heart disease: time for a better understanding. J AM Coll Cardiol. 2013; 61(5): 511-23. doi: 10.1016/j.jacc.2012.06.063 PMID: 23369416
4. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003; 22:77-84. PMID: 12544413
5. Kramer AS, Lazzarotto AR, Sprinz E, Manfroi WC. Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV. Arq Bras Cardiol. 2009; 93:561-8. PMID: 20084320
6. Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. CurrAtheroscler Rep. 2011; 13:51-6. doi: 10.1007/s11883-010-0152-1 PMID: 21181310
7. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'. Curr Opin Lipi-dol. 2004; 15:59-67. PMID: 15166810
8. Jani RH, Kansagra K, Jain M, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominant PPARa agonist and moderate y agonist activity in healthy human subjects. Clin Drug Investigation 2013; doi: 10.1007/s40261-013-0128-3
9. Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Shashank J. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes TechnolTher. 2014; 16(2):63-71. doi: 10.1089/dia.2013. 0253 PMID: 24138536
10. Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V, et al. A multicenter, prospective, randomized double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mgin diabetic dyslipidemia (PRESS V). J Diabetes SciTechnol. 2014; 8 (1):132-141. PMID: 24876549
11. McGoldrickC; Leen CLS. The management of dyslipidemias in Antiretroviral-treated HIV Infection: A Systematic Review. HIV Med.2007; 8(6):325-334. PMID: 17661840
12. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet.1998; 352:1031-1032. PMID: 9759748
13. Bonnet F, Balestre E, Thiebaut R, Mercié P, Dupon M, Morlat P, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med.2004; 5:133-139.
14. Palacios R, Santos J, Gonzalez M, Ruiz J, Valdivielso P, Márquez M, et al. Efficacy and safety of fenofi-brate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J Acquir. Immune Defic Syndr. 2002; 31:251-253. PMID: 12394806
15. Badiou S, De Boever MC, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004; 172:273-279. PMID: 15019537
16. Caramelli B, de Bernoche CY, Sartori AM, Sposito AC, Santos RD, Monachini MC, et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis. 2001; 5:332-338. PMID: 11980596
17. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS. 1999; 13:868-869. PMID: 10357393
18. Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, et al. A randomized, double-blind study of gemfibrozil forthe treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002; 16:2195-2200. PMID: 12409741
19. Rao A, D'Amico S, Balasubramanyam A, Maldonado M. Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci.2004; 327:315-318. PMID: 15201643
20. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-188. PMID: 11545549
21. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection.2002; 30:26-31. PMID: 11876511
22. Yki-Jarvinen H. Thiazolidinediones. N EnglJ Med. 2004; 351:1106-1118. PMID: 15356308
23. Bennett MT, Johns KW, Bondy GP. Current and future treatments of HIV-associateddyslipidemia. Future Lipidology. 2008; 3(2): 175-188.
24. Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses. 2005; 21:757-767. PMID: 16218799
25. Grundy SM, Brewer HB, Cleeman JI Jr, Smith SC, LenfantC Jr. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004; 109:433-438. PMID: 14744958
26. Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 00:000-000.
27. Eoin RF, Patrick WGM. HIV and HAART-Associated Dyslipidemia. The Open Cardiovascular Medicine Journal. 2011; 5:49-63. doi: 10.2174/1874192401105010049 PMID: 21643501
28. Yiqing S, JoAnn EM, Lesley T, Barbara VH, Lewis HK, Lauren N, Nader R, Simin L. Insulin Sensitivity and Insulin Secretion Determined by Homeostasis Model Assessment (HOMA) and Risk of Diabetes in a Multiethnic Cohort of Women: The Women's Health InitiativeObservational Study. Diabetes Care. 2007; 30(7): 1747-1752. PMID: 17468352
29. Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab. 2003; 285:E490-E497. PMID: 12746213
30. Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, Goebel FD, Demant T. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acq Immune Defic Syndr. 2001; 26:225-235.
31. Shahmanesh M, Das S, Stolinski M, Shojaee-Moradie F, Jackson NC, Jefferson W, Cramb R, Nightingale P, Umpleby AM. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodefi ciency virusinfected patients with mild dyslipidemia. J Clin EndocrinolMetab. 2005; 90:755-760.
32. Baril L, Beucler I, Valantin MA, Bruckert E, Bonnefont-Rousselot D, Coutellier A, Caumes E, Katlama C, Bricaire F. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS(London, England). 2001; 15:415-417.
33. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V. Atherogenic dyslipidemia in HIV-infected individualstreated with protease inhibitors. The Swiss HIV Cohort Study. Circulation.1999; 100:700-705. PMID: 10449690
34. Anuurad E, Thomas-Geevarghese A, Devaraj S, Albu J, Minolfo R, El-Sadr WM, Lu G, Karmally W, Berglund L. Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis. 2008; 198:192-197. PMID: 17996872
35. Michael LG. Evaluation and management of dyslipidemia in patient with HIV. J Gen Intern Med. 2002; 17: 797-810. PMID: 12390557